Journal
NEUROBIOLOGY OF DISEASE
Volume 36, Issue 1, Pages 142-150Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2009.07.016
Keywords
EGFR; AG1478/PD168393; Inhibitory CNS myelin; Glia; Neurotrophins; DRGN; Neurite outgrowth
Categories
Funding
- Wellcome Trust [065920]
- Biotechnology and Biological Sciences Research Council (BBSRC) [G181986]
- International Spinal Research Trust [NRB099]
- University of Birmingham Scientific Projects Committee
Ask authors/readers for more resources
Administration of epidermal growth factor receptor (EGFR) inhibitors (e. g. AG1478/PD168393) promotes central nervous system (CNS) axon regeneration in vivo by an unknown mechanism. Here, we show that EGFR activation is not required for AG1478-/PD168393-induced neurite outgrowth in cultures of dorsal root ganglion neurons (DRGN) with added inhibitory CNS myelin extract (CME), but is mediated by the paracrine and autocrine actions of the glia-/neuron-derived neurotrophins (NT) NGF, BDNF and NT-3 through Trk signalling in DRGN potentiated by elevated cAMP levels. The DRGN neurite growth seen in CME-inhibited cultures treated with AG1478 is eradicated by blocking Trk signalling but undiminished after siRNA knockdown of >90% EGFR. Moreover, addition of the combined triplet of NT restores neurite outgrowth in CME-inhibited cultures, when cAMP levels are raised. Accordingly, we suggest that chemical EGFR inhibitors act independently of EGFR, inducing glia and neurons to secrete NT and raising cAMP levels in DRG cultures, leading to Trk-dependent disinhibited DRGN neurite outgrowth. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available